Moreover, while anti-IFNα/β antibodies that prevent IFNα/β-induced inflammation have been described in patients with autoimmune polyendocrinopathy syndrome, SLE and COVID-19 (25, 50, 51), it is unclear whether they are produced by patients with SCD and whether they contribute to the variable disease progression during viral infection. This evidence concerns the gene IFNA2 and viral infectious disease.